Routine Screening for Chronic Human Immunodeficiency Virus Infection: Why Don't the Guidelines Agree?
Author:
Open Access
- 19 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Epidemiologic Reviews
- Vol. 33 (1) , 7-19
Abstract
Infection with human immunodeficiency virus remains a major public health problem in the United States. Prominent guidelines from the U.S. Preventive Services Task Force and the Centers for Disease Control and Prevention differ in their recommendations on whether and how to screen adults and adolescents not known to be at higher risk. These discrepancies have led to controversy and debate as well as confusion among clinicians. This article reviews principles of screening, explains specific issues related to screening for human immunodeficiency virus, reviews the discrepancies between the US Preventive Services Task Force and the Centers for Disease Control and Prevention guidelines and the methods used in each guideline, and describes potential reasons for the discrepancies. The case of screening for human immunodeficiency virus illustrates how discrepancies between guidelines may be related to different guideline development methods as well as the different perspectives of the guideline development groups.Keywords
This publication has 64 references indexed in Scilit:
- Effect of Early versus Deferred Antiretroviral Therapy for HIV on SurvivalNew England Journal of Medicine, 2009
- Estimation of HIV Incidence in the United StatesJAMA, 2008
- Lipid Screening and Cardiovascular Health in ChildhoodPediatrics, 2008
- Relation between HIV viral load and infectiousness: a model-based analysisThe Lancet, 2008
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Changing the Paradigm for HIV Testing — The End of ExceptionalismNew England Journal of Medicine, 2006
- Initiation of Highly Active Antiretroviral Therapy at CD4+T Lymphocyte Counts of >350 cells/mm3: Disease Progression, Treatment Durability, and Drug ToxicityClinical Infectious Diseases, 2003
- Interpretation of cost-effectiveness analysesJournal of General Internal Medicine, 1998
- Insights on the Pathogenicity of Human T-Lymphotropic/Leukemia Virus Types I and IIJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996